Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Nov 5, 2009

Premium

Title: siRNA Targeting Cyclin-Dependent Kinase Inhibitor 1B

Number: 7,612,196

Filed: Oct. 30, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.”


Title: Retroviral Vectors for Delivery of Interfering RNA

Number: 7,612,195

Filed: Oct. 21, 2004 PCT Filed: Oct. 21, 2004

Lead Inventor: Dorre Grueneberg, Aventis Pharmaceuticals (Sanofi-Aventis)

The patent, its abstract states, claims “retroviral vectors for delivering interfering RNA into cells.”


Title: Reprogramming a Cell by Inducing a Pluripotent Gene Through RNA Interference

Number: 20090269763

Filed: April 7, 2009

Lead Inventor: Kenneth Eilertsen, NuPotential

The invention relates to “methods, compositions, and kits for reprogramming a cell,” the patent application’s abstract states. “In one embodiment, the invention relates to a method for inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the method comprises inhibiting the expression of a gene that codes for a protein involved in transcriptional repression. In yet another embodiment, the invention relates to a reprogrammed cell or an enriched population of reprogrammed cells that can have characteristics of an ES-like cell, which can be re- or trans-differentiated into a differentiated cell type.”


Title: Modified siRNA Molecules and Uses Thereof

Number: 20090270481

Filed: Jan. 23, 2009

Lead Inventor: Ian MacLachlan, Protiva Biotherapeutics (Tekmira Pharmaceuticals)

The invention, the patent application’s abstract states, “provides chemically modified siRNA molecules and methods of using such siRNA molecules to silence target gene expression. Advantageously, the modified siRNA of the present invention is less immunostimulatory than its corresponding unmodified siRNA sequence and retains RNAi activity against the target sequence.”

The invention also provides “nucleic acid-lipid particles comprising a modified siRNA, a cationic lipid, and a non-cationic lipid, which can further comprise a conjugated lipid that inhibits aggregation of particles,” the abstract adds. “The … invention further provides methods of silencing gene expression by administering a modified siRNA to a mammalian subject. Methods for identifying and/or modifying an siRNA having immunostimulatory properties are also provided.”


Title: Human RNase III and Uses Thereof

Number: 20090270486

Filed: Dec. 22, 2008

Inventor: Stanley Crooke, Isis Pharmaceuticals

The invention “provides polynucleotides encoding human RNase III and polypeptides encoded thereby,” the patent application’s abstract states. “Methods of using said polynucleotides and polypeptides are also provided.”


Title: Compositions and Methods for Inhibiting the Synthesis or Expression of MMP-1

Number: 20090270487

Filed: Jan. 12, 2009

Lead Inventor: Colby Wyatt, Dartmouth Hitchcock Medical Center

The invention “relates to the specific inhibition of matrix metalloproteinase 1 using agents which inhibit the synthesis or expression of MMP-1,” including siRNAs, the patent application’s abstract states. “Such agents are useful for suppressing invasion or metastasis of a tumor cell and in the treatment, prevention and management of cancer.”


Title: Modulation of Tudor-SN Expression

Number: 20090270491

Filed: June 19, 2009

Lead Inventor: Nicholas Dean, Isis Pharmaceuticals

The patent application, its abstract states, claims “compounds, compositions, and methods … for modulating the expression of Tudor-SN. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Tudor-SN. Methods of using these compounds for modulation of Tudor-SN expression and for diagnosis and treatment of diseases and conditions associated with expression of Tudor-SN are provided.”

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.